Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies

Indatuximab ravtansine is a monoclonal antibody-linked cytotoxic agent that specifically targets CD138-expressing cells. Monotherapy has been shown to significantly inhibit multiple myeloma tumour growth in vivo and improve host survival. Here, we show that in most cell lines tested, indatuximab rav...

Descripción completa

Detalles Bibliográficos
Autores principales: Schönfeld, Kurt, Zuber, Chantal, Pinkas, Jan, Häder, Thomas, Bernöster, Katrin, Uherek, Christoph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5225632/
https://www.ncbi.nlm.nih.gov/pubmed/28077160
http://dx.doi.org/10.1186/s13045-016-0380-0
_version_ 1782493548886622208
author Schönfeld, Kurt
Zuber, Chantal
Pinkas, Jan
Häder, Thomas
Bernöster, Katrin
Uherek, Christoph
author_facet Schönfeld, Kurt
Zuber, Chantal
Pinkas, Jan
Häder, Thomas
Bernöster, Katrin
Uherek, Christoph
author_sort Schönfeld, Kurt
collection PubMed
description Indatuximab ravtansine is a monoclonal antibody-linked cytotoxic agent that specifically targets CD138-expressing cells. Monotherapy has been shown to significantly inhibit multiple myeloma tumour growth in vivo and improve host survival. Here, we show that in most cell lines tested, indatuximab ravtansine acts additively or even synergistically with clinically approved therapies for treatment of multiple myeloma. In addition, in vivo mouse xenograft models confirmed the activity of indatuximab ravtansine in combination with lenalidamide and lenalidomide/dexamethasone. Indatuximab ravtansine may therefore be a suitable combination partner for multiple myeloma, and a clinical study is ongoing. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13045-016-0380-0) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5225632
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-52256322017-01-17 Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies Schönfeld, Kurt Zuber, Chantal Pinkas, Jan Häder, Thomas Bernöster, Katrin Uherek, Christoph J Hematol Oncol Letter to the Editor Indatuximab ravtansine is a monoclonal antibody-linked cytotoxic agent that specifically targets CD138-expressing cells. Monotherapy has been shown to significantly inhibit multiple myeloma tumour growth in vivo and improve host survival. Here, we show that in most cell lines tested, indatuximab ravtansine acts additively or even synergistically with clinically approved therapies for treatment of multiple myeloma. In addition, in vivo mouse xenograft models confirmed the activity of indatuximab ravtansine in combination with lenalidamide and lenalidomide/dexamethasone. Indatuximab ravtansine may therefore be a suitable combination partner for multiple myeloma, and a clinical study is ongoing. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13045-016-0380-0) contains supplementary material, which is available to authorized users. BioMed Central 2017-01-11 /pmc/articles/PMC5225632/ /pubmed/28077160 http://dx.doi.org/10.1186/s13045-016-0380-0 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Letter to the Editor
Schönfeld, Kurt
Zuber, Chantal
Pinkas, Jan
Häder, Thomas
Bernöster, Katrin
Uherek, Christoph
Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies
title Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies
title_full Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies
title_fullStr Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies
title_full_unstemmed Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies
title_short Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies
title_sort indatuximab ravtansine (bt062) combination treatment in multiple myeloma: pre-clinical studies
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5225632/
https://www.ncbi.nlm.nih.gov/pubmed/28077160
http://dx.doi.org/10.1186/s13045-016-0380-0
work_keys_str_mv AT schonfeldkurt indatuximabravtansinebt062combinationtreatmentinmultiplemyelomapreclinicalstudies
AT zuberchantal indatuximabravtansinebt062combinationtreatmentinmultiplemyelomapreclinicalstudies
AT pinkasjan indatuximabravtansinebt062combinationtreatmentinmultiplemyelomapreclinicalstudies
AT haderthomas indatuximabravtansinebt062combinationtreatmentinmultiplemyelomapreclinicalstudies
AT bernosterkatrin indatuximabravtansinebt062combinationtreatmentinmultiplemyelomapreclinicalstudies
AT uherekchristoph indatuximabravtansinebt062combinationtreatmentinmultiplemyelomapreclinicalstudies

Ejemplares similares